Since the presentation of trials such as the Intergroup N9741 study (National Cancer Institute of Canada CO.15) and the MOSAIC (Multicenter International Study of Oxaliplatin/5-FU–LV in the Adjuvant Treatment of Colon Cancer) trial at the 2003 American Society of Clinical Oncology meeting, oncologists have broadly accepted that oxaliplatin is part of the standard management of colorectal cancer...

Increased utilization of evaluation results has been the primary rationale for the development of participatory or stakeholder approaches. The assumption is that participation by various constituents in the evaluation process will increase their understanding of and commitment to the use of evaluation results. Another rationale for implementing a participatory evaluation approach is empowerment...